Results 111 to 120 of about 3,606 (169)
A case of bilateral stellate nonhereditary idiopathic foveomacular retinoschisis with 14-month follow-up: clinical features, OCT findings and treatment outcome. [PDF]
BMC OphthalmolHassanpoor N +3 more
europepmc +1 more source
Severe Pulmonary Coccidioidomycosis Treated With Systemic Corticosteroids in an Adolescent Child. [PDF]
Case Rep PediatrShinozaki R +3 more
europepmc +1 more source
Advanced bilateral glaucoma decades after first-generation Fyodorov 'collar-button' anterior-posterior phakic intraocular lens implantation: a case report and clinical management considerations. [PDF]
Front Ophthalmol (Lausanne)Sarnat-Kucharczyk M +5 more
europepmc +1 more source
Drug induced hyperpigmentation: systematic review and meta-analysis. [PDF]
Front Med (Lausanne)Alharithy R +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Pharmacokinetics of Dorzolamide
Clinical Pharmacokinetics, 2002Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and therefore to the desired therapeutic ...
Jens, Martens-Lobenhoffer +1 more
openaire +2 more sources
A Trial of Dorzolamide for Glaucoma
Ophthalmic Surgery, Lasers and Imaging Retina, 1998* BACKGROUND AND OBJECTIVE: To determine whether the effectiveness of dorzolamide changes when the drug is used under routine clinical conditions versus the more ideal conditions of a clinical trial. * PATIENTS AND METHODS: A total of 118 eyes of 65 patients were assessed.
W E, Gillies, A M, Brooks
openaire +2 more sources
Seminars in Ophthalmology, 1997
Major advances in pharmacological research have led to the introduction of four new and potent topical ocular hypotensive agents within the past few years. The federal government requires stringent premarket testing to prove efficacy and safety. These safety and efficacy studies are performed on a finite number of patients over a limited period of time.
Elizabeth K. Donohue, Jacob T. Wilensky
openaire +1 more source
Major advances in pharmacological research have led to the introduction of four new and potent topical ocular hypotensive agents within the past few years. The federal government requires stringent premarket testing to prove efficacy and safety. These safety and efficacy studies are performed on a finite number of patients over a limited period of time.
Elizabeth K. Donohue, Jacob T. Wilensky
openaire +1 more source